Share on StockTwits

Merck & Co (NYSE:MRK) EVP Adam H. Schechter sold 18,000 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $55.61, for a total transaction of $1,000,980.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

MRK has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co in a research note on Thursday, February 6th. They now have a $56.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Merck & Co from $55.00 to $60.00 in a research note on Thursday, February 6th. Finally, analysts at Argus raised their price target on shares of Merck & Co from $54.00 to $62.00 in a research note on Wednesday, February 5th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company’s stock. Merck & Co has an average rating of “Buy” and a consensus price target of $55.56.

Merck & Co (NYSE:MRK) traded down 0.21% during mid-day trading on Thursday, hitting $54.885. The stock had a trading volume of 4,390,136 shares. Merck & Co has a one year low of $40.83 and a one year high of $55.75. The stock’s 50-day moving average is $51.96 and its 200-day moving average is $48.81. The company has a market cap of $160.4 billion and a P/E ratio of 37.41.

Merck & Co (NYSE:MRK) last released its earnings data on Wednesday, February 5th. The company reported $0.88 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.88. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $11.39 billion. During the same quarter last year, the company posted $0.83 earnings per share. Merck & Co’s revenue was down 3.6% compared to the same quarter last year. Analysts expect that Merck & Co will post $3.44 EPS for the current fiscal year.

Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.